{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:28:44Z","timestamp":1787506124340,"version":"build-2736575974"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ovarian cancer (OC) represents a common neoplasm within the female reproductive tract. The prognosis for patients diagnosed at advanced stages is unfavorable, primarily attributable to the absence of reliable screening markers for early detection. An elevated neutrophil-to-lymphocyte ratio (NLR) serves as an indicator of host inflammatory response and has been linked to poorer overall survival (OS) across various cancer types; however, its examination in OC remains limited. This study seeks to identify combination diagnostic and prognostic markers for OC, aiming to improve diagnostic and prognostic efficacy, especially in the early stages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed the targeted biomarkers in a cohort of 104 OC patients and 100 controls, which comprised 50 patients with benign ovarian tumors and 50 healthy women, using enzyme-linked immunosorbent assay (ELISA) and complete blood counting (CBC). After validating the biomarker panel, we compared the expression levels of the biomarkers in OC patients with various clinical features to assess their relevance. A biomarker panel was developed and validated with an independent cohort of 70 OC patients and 60 controls, including 30 with benign ovarian tumors and 30 healthy women. We evaluated the diagnostic accuracy using the area under the receiver-operating characteristic (ROC) curve and overall survival analysis was used for prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The results from ELISA and CBC analyses indicated that the NLR was significantly higher in patients with OC. This elevation was especially notable in those with advanced stages of the disease, lymph node metastasis, and ascites. The diagnostic performance of the NLR, when combined with CA125 and HE4, outperformed each marker used individually, especially when compared to the traditional combination of CA125 and HE4. Importantly, we observed similar results in patients with early-stage ovarian cancer and those with low levels of CA125 and HE4. In addition, these results suggest that NLR combined with CA125 and HE4 levels in OC patients have significant prognostic value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The effective combination of serum NLR, CA125, and HE4 significantly enhances diagnostic efficiency in patients with OC. Serum NLR, CA125, and HE4 levels were identified as independent prognostic markers for OC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2024.1494051","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T09:15:03Z","timestamp":1736932503000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Serum NLR combined with CA125 and HE4 improves the diagnostic and prognostic efficiency in patients with ovarian cancer"],"prefix":"10.3389","volume":"14","author":[{"given":"Yun","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiabing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaohong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1999","article-title":"Adipocyte-induced FABP4 expression in ovarian cancer cells promotes metastasis and mediates carboplatin resistance","volume":"80","author":"Mukherjee","year":"2020","journal-title":"Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-09899-8","article-title":"Clinical significance of mesenteric lymph node involvement in the pattern of liver metastasis in patients with ovarian cancer","volume":"28","author":"Tanaka","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002580","article-title":"Ovarian cancer prevention and screening","volume":"131","author":"Menon","year":"2018","journal-title":"Obstet Gynecol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma","volume":"68","author":"Bast","year":"1981","journal-title":"J Clin Invest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9098(200012)75:4<264::AID-JSO7>3.0.CO;2-Q","article-title":"Benign conditions associated with raised serum CA-125 concentration","volume":"75","author":"Buamah","year":"2000","journal-title":"J Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951115)76:10+<2092::AID-CNCR2820761331>3.0.CO;2-T","article-title":"Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection","volume":"76","author":"Berek","year":"1995","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgyn.2013.09.030","article-title":"Ovarian tumor markers of presumed benign ovarian tumors","volume":"42","author":"Lahlou","year":"2013","journal-title":"J Gynecol Obstet Biol Reprod (Paris)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13048-019-0503-7","article-title":"Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review","volume":"12","author":"Dochez","year":"2019","journal-title":"J Ovarian Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252011239","article-title":"The role of tumor biomarkers in tailoring the approach to advanced ovarian cancer","volume":"25","author":"Tonti","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.3802\/jgo.2024.35.e104","article-title":"Targeting BRAF pathway in low-grade serous ovarian cancer","volume":"35","author":"Perrone","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgp127","article-title":"Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability","volume":"30","author":"Colotta","year":"2009","journal-title":"Carcinogenesis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04046-0","article-title":"Inflammation and cancer: back to Virchow","volume":"357","author":"Balkwill","year":"2001","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040958","article-title":"Neutrophil to lymphocyte ratio as prognostic and predictive factor in breast cancer patients: A systematic review","volume":"12","author":"Corbeau","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16429","article-title":"Pretreatment neutrophil-to-lymphocyte ratio: A prognostic biomarker of survival in patients with epithelial ovarian cancer","volume":"13","author":"John-Olabode","year":"2021","journal-title":"Cureus"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-021-00752-6","article-title":"Systemic inflammation markers and cancer incidence in the UK Biobank","volume":"36","author":"N\u00f8st","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12890-022-01901-7","article-title":"The MLR, NLR, PLR and D-dimer are associated with clinical outcome in lung cancer patients treated with surgery","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Pulm Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100431","article-title":"Clinical epidemiology of gallbladder cancer in North-Central India and association of immunological markers, NLR, MLR and PLR in the diagnostic\/prognostic prediction of GBC","volume":"28","author":"Singh","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i9.2807","article-title":"Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis","volume":"21","author":"Yang","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2018.10.042","article-title":"Diagnosis and survival values of neutrophil-lymphocyte ratio (NLR) and red blood cell distribution width (RDW) in esophageal cancer","volume":"488","author":"Han","year":"2019","journal-title":"Clin Chim Acta"},{"key":"B23","doi-asserted-by":"publisher","first-page":"9146042","DOI":"10.1155\/2020\/9146042","article-title":"Diagnostic sensitivity of NLR and PLR in early diagnosis of gastric cancer","volume":"2020","author":"Fang","year":"2020","journal-title":"J Immunol Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-1814-0","article-title":"Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients","volume":"19","author":"Azab","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-008-0516-3","article-title":"Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment","volume":"58","author":"Cho","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0502178102","article-title":"Serum protein markers for early detection of ovarian cancer","volume":"102","author":"Mor","year":"2005","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i18.5511","article-title":"Proteomic identification of tumor biomarkers associated with primary gallbladder cancer","volume":"20","author":"Huang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.05.004","article-title":"Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients","volume":"150","author":"Baert","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.v147.2","article-title":"Diagnostic value of serum D-dimer, CA125, and neutrophil-to-lymphocyte ratio in differentiating ovarian cancer and endometriosis","volume":"147","author":"Chen","year":"2019","journal-title":"Int J Gynaecol Obstet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12810","article-title":"Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy","volume":"7","author":"Ha","year":"2016","journal-title":"Oncotarget"},{"key":"B32","doi-asserted-by":"publisher","first-page":"20056","DOI":"10.1038\/s41598-020-77167-y","article-title":"Clinical usefulness of high levels of C-reactive protein for diagnosing epithelial ovarian cancer","volume":"10","author":"Yang","year":"2020","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051593","article-title":"A dual biomarker TK1 protein and CA125 or HE4-based algorithm as a better diagnostic tool than ROMA index in early detection of ovarian cancer","volume":"15","author":"Cvii\u010d","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0240418","article-title":"A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients","volume":"15","author":"Leandersson","year":"2020","journal-title":"PloS One"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1494051\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T09:15:06Z","timestamp":1736932506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1494051\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":34,"alternative-id":["10.3389\/fonc.2024.1494051"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1494051","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,20]]},"article-number":"1494051"}}